"Studies have shown that point-of-care antigen tests with sufficient sensitivity and specificity can facilitate diagnosis, treatment, and mitigate reliance on slower, conventional laboratory-based testing and infrastructure," Brian DuChateau, vice president of Clinical and Scientific Affairs at LumiraDx, said in a statement. "However, the COVID-19 pandemic not only demonstrated the need for this type of testing, but also showed how quick result turn-around time can mitigate rates of infection."

DuChateau added that LumiraDx's actively controlled microfluidic testing technology brings lab-comparable performance to the point-of-need, "supporting several unique use cases during the pandemic and beyond."

BrightInsight launches digital diagnostics platform at AACC
BrightInsight on Monday announced the launch of its digital Connected Diagnostics Platform at the 2022 AACC Annual Scientific Meeting and Clinical Lab...

Cytovale to present new data on rapid sepsis test at AACC
Cytovale said Monday that it will present new data at AACC 2022 about its 10-minute IntelliSep test for sepsis and its associated system.

Companies announce new products ahead of AACC 2022
Several companies have announced the launch of laboratory diagnostic products in advance of AACC 2022.

DiaSorin nabs FDA clearance for infectious disease blood test
Saluggia, Italy-based DiaSorin on Friday announced that it has obtained U.S. Food and Drug Administration (FDA) clearance for the Liaison MeMed BV, its...

Survey finds low morale among lab professionals
Lighthouse Lab Services on Wednesday announced the results of its first wage and morale survey of medical laboratory professionals, saying that despite...

Beckman, Scopio to partner on blood smear platforms
Beckman Coulter Diagnostics on Wednesday announced that it has partnered with Scopio Labs to accelerate adoption of Scopio's next-generation peripheral...

AACC sees rise in impact of medical laboratory journal
AACC recently announced that the impact factor of its journal Clinical Chemistry has risen to 12.167 in the 2021 Clarivate Journal Citation Reports.